Acumen Pharmaceuticals, Inc.(ABOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABOS Acumen Pharmaceuticals, Inc.

Closed 04-03 16:00:00 EDT

0.9880

-0.0920

-8.52%

盘后0.9880

+0.00000.00%

16:48 EDT

High1.06	Low0.9802	Vol320.46K
Open1.05	D1 Closing1.08	Amplitude6.93%
Mkt Cap59.85M	Tradable Cap32.40M	Total Shares60.57M
T/O321.52K	T/O Rate0.98%	Tradable Shares32.79M
P/B0.33	ROE-45.60%	EPS-1.71
52wk High4.06	52wk Low0.9802	P/E-0.58
Dividend0.00	Div.Yield0.00	ROA-25.95%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ABOS","market":"US","secType":"STK","nameCN":"Acumen Pharmaceuticals, Inc.","latestPrice":0.988,"timestamp":1743710400000,"preClose":1.08,"halted":0,"volume":320456,"hourTrading":{"tag":"盘后","latestPrice":0.988,"preClose":0.988,"latestTime":"16:48 EDT","volume":3153,"amount":3115.584,"timestamp":1743713282261},"delay":0,"floatShares":32793089,"shares":60573425,"eps":-1.705106,"marketStatus":"Closed","change":-0.092,"latestTime":"04-03 16:00:00 EDT","open":1.05,"high":1.055,"low":0.9802,"amount":321517.569057,"amplitude":0.069259,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.705106,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743753600000},"marketStatusCode":5,"adr":0,"listingDate":1625112000000,"exchange":"NASDAQ","adjPreClose":1.08,"postHourTrading":{"tag":"盘后","latestPrice":0.988,"preClose":0.988,"latestTime":"16:48 EDT","volume":3153,"amount":3115.584,"timestamp":1743713282261},"volumeRatio":1.207937,"impliedVol":0.6471,"impliedVolPercentile":0.2789},"requestUrl":"/m/hq/s/ABOS","defaultTab":"news","newsList":[{"id":"2524191062","title":"Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2524191062","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524191062?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:00","pubTimestamp":1743505202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nTUA7FW8VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK7508","CLYM","VERV","IMU.AU","BK4139","LENZ","SLDB","ABOS","BK7067"],"gpt_icon":0},{"id":"2523689127","title":"Acumen Pharmaceuticals’ Promising Alzheimer’s Strategy Earns Buy Rating with Revised Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2523689127","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523689127?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 01:55","pubTimestamp":1743184513,"startTime":"0","endTime":"0","summary":"Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Acumen Pharmaceuticals (ABOS – Research Report). The associated price ta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/acumen-pharmaceuticals-promising-alzheimers-strategy-earns-buy-rating-with-revised-price-target?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/acumen-pharmaceuticals-promising-alzheimers-strategy-earns-buy-rating-with-revised-price-target?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABOS"],"gpt_icon":0},{"id":"2522579920","title":"Acumen Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522579920","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522579920?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:45","pubTimestamp":1743165900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABOS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 28, 2025 08:45 ET (12:45 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABOS"],"gpt_icon":0},{"id":"2522410527","title":"UBS Cuts Price Target on Acumen Pharmaceuticals to $4 From $6, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2522410527","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522410527?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:23","pubTimestamp":1743161015,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals (ABOS) has an average rating of buy and mean price target of $8.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABOS"],"gpt_icon":0},{"id":"2522351488","title":"Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Highlights: Strong Financial Position ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2522351488","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522351488?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 15:01","pubTimestamp":1743145262,"startTime":"0","endTime":"0","summary":"Cash and Marketable Securities: $231.5 million as of the end of 2024.R&D Expenses: $93.8 million in 2024, increased due to ALTITUDE-AD trial support.G&A Expenses: $20.2 million in 2024, roughly flat compared to the prior year.Net Loss: $102.3 million in 2024, after accounting for interest income.GuruFocus has detected 3 Warning Signs with ABOS.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Acumen Pharmaceuticals Inc  successfully completed enrollment of 542 participants in the ALTITUDE-AD Phase II study ahead of schedule, demonstrating strong operational execution.Acumen Pharmaceuticals Inc  has a strong financial position with $231.5 million in cash and marketable securities, expected to support operations into the first half of 2027.The company is actively engaging with the research community and clinical investigators, enhancing the recognition and potential of sabirnetug as a next-generation treatment for early Alzheimer's diseas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acumen-pharmaceuticals-inc-abos-q4-070102406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABOS"],"gpt_icon":0},{"id":"2522590379","title":"Q4 2024 Acumen Pharmaceuticals Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2522590379","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522590379?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 13:00","pubTimestamp":1743138047,"startTime":"0","endTime":"0","summary":"Alex Braun; Head of Investor Relations; Acumen Pharmaceuticals Inc. Daniel O'Connell; Chief Executive Officer, Director; Acumen Pharmaceuticals Inc. W. Matthew Zuga; Chief Financial Officer, Chief Business Officer; Acumen Pharmaceuticals Inc. James Doherty; President, Chief Development Officer; Acumen Pharmaceuticals Inc. Eric Siemers; Chief Medical Officer; Acumen Pharmaceuticals Inc. Thanks, Alex. Good morning, everyone, and thanks for joining us today. Acumen entered 2024 from a position of strength, stemming from our positive results for sabirnetug in our INTERCEPT-AD Phase I study in early Alzheimer's patients. In INTERCEPT AD, sabirnetug was well tolerated, demonstrated novel target engagement of A-beta oligomers and produce consistent effects on imaging and fluid biomarkers in a dose-dependent manner.I'm proud though not surprised that our talented team leaned into this","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-acumen-pharmaceuticals-inc-050047124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABOS"],"gpt_icon":0},{"id":"2522095173","title":"Acumen Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522095173","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522095173?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 21:31","pubTimestamp":1743082268,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryAcumen Pharmaceuticals Inc ABOS.OQ reported a quarterly adjusted loss of 62 cents per share for the quart","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nL5N3QA18Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABOS"],"gpt_icon":0},{"id":"2522759743","title":"Acumen Pharmaceuticals FY 2024 EPS $(1.71) Misses $(1.55) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522759743","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522759743?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:03","pubTimestamp":1743073423,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals (NASDAQ:ABOS) reported FY 2024 EPS $(1.71) Misses $(1.55) Estimate.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44510836/acumen-pharmaceuticals-fy-2024-eps-1-71-misses-1-55-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABOS"],"gpt_icon":0},{"id":"2522667375","title":"BRIEF-Acumen Pharmaceuticals, Inc. FY Income From Operations USD -114.017 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522667375","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522667375?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073246,"startTime":"0","endTime":"0","summary":"BRIEF-Acumen Pharmaceuticals, Inc. FY Income From Operations USD -114.017 Million\n\n\nMar 27 (Reuters) - Acumen Pharmaceuticals, Inc. FY net income USD -102.329 million.\n\nFY operating expenses USD 114.017 million\nFY basic EPS USD -1.71","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX40B324:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABOS","BK4139","BK4539"],"gpt_icon":0},{"id":"2522137530","title":"Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522137530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522137530?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA630RNY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABOS","BK4539","BK4139"],"gpt_icon":0},{"id":"2522837553","title":"Acumen Pharmaceuticals, Inc. FY Net Income USD -102.329 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522837553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522837553?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX40B324:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABOS","BK4539","BK4139"],"gpt_icon":0},{"id":"2522755633","title":"Acumen Pharmaceuticals, Inc. FY Basic EPS USD -1.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2522755633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522755633?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX40B324:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABOS","BK4139","BK4539"],"gpt_icon":0},{"id":"2522595375","title":"Acumen Pharmaceuticals, Inc. FY Income From Operations USD -114.017 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522595375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522595375?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX40B324:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABOS","BK4139","BK4539"],"gpt_icon":0},{"id":"2522375523","title":"Acumen Pharmaceuticals, Inc. FY Operating Expenses USD 114.017 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375523","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375523?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX40B324:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABOS","BK4539","BK4139"],"gpt_icon":0},{"id":"2522759233","title":"Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522759233","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522759233?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"Enrollment complete for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug  for the treatment of early Alzheimer’s disease. Topline results from the Phase 1 study investigating a subcutaneous sabirnetug formulation support further development of this dosing option for patients. Cash, cash equivalents and marketable securities of $231.5 million as of Dec. 31, 2024, expected to support current clinical and operational activities into the first half of 2027. In January 2025, the Company announced that the Journal of Prevention of Alzheimer’s Disease  published the results of its Phase 1 INTERCEPT-AD study, demonstrating that sabirnetug  was generally well-tolerated with dose- and exposure-dependent target engagement and reduction in amyloid plaques.The publication titled “INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease” is available online here.The publication titled “Biofluid biomarker ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acumen-pharmaceuticals-reports-financial-results-110000269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4539","ABOS"],"gpt_icon":0},{"id":"2522742168","title":"BRIEF-Acumen Pharmaceuticals Completes Enrollment Of Altitude-Ad, A Phase 2 Clinical Trial Of Sabirnetug (Acu193) In Early Alzheimer’S Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2522742168","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522742168?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:07","pubTimestamp":1742990844,"startTime":"0","endTime":"0","summary":"BRIEF-Acumen Pharmaceuticals Completes Enrollment Of Altitude-Ad, A Phase 2 Clinical Trial Of Sabirnetug (Acu193) In Early Alzheimer’S DiseaseMarch 26 (Reuters) - Acumen Pharmaceuticals Inc ABOS.O:ACU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA7DG50M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","ABOS"],"gpt_icon":0},{"id":"2522874180","title":"Acumen Pharmaceuticals Inc - Topline Results Expected in Late 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2522874180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522874180?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:00","pubTimestamp":1742990401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA7DG50M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABOS","BK4139","BK4539"],"gpt_icon":0},{"id":"2522720871","title":"Acumen Pharmaceuticals Completes Enrollment of Altitude-Ad, a Phase 2 Clinical Trial of Sabirnetug (Acu193) in Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2522720871","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522720871?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:00","pubTimestamp":1742990401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA7DG50M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","ABOS","BK4139"],"gpt_icon":0},{"id":"2522611073","title":"Acumen Pharmaceuticals Inc  expected to post a loss of 48 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522611073","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522611073?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:39","pubTimestamp":1742906360,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals Inc  expected to post a loss of48cents a share - Earnings Preview Acumen Pharmaceuticals Inc ABOS.OQ ABOS.O is expected to show no change in quarterly revenue when it reports  r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL5N3Q80ZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABOS"],"gpt_icon":0},{"id":"2521281301","title":"Acumen Pharmaceuticals Inc  expected to post a loss of 48 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521281301","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521281301?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 21:09","pubTimestamp":1742562546,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals Inc  expected to post a loss of48cents a share - Earnings Preview Acumen Pharmaceuticals Inc ABOS.OQ ABOS.O is expected to show no change in quarterly revenue when it reports  r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q416D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABOS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acumenpharm.com","stockEarnings":[{"period":"1week","weight":-0.069},{"period":"1month","weight":-0.0609},{"period":"3month","weight":-0.4162},{"period":"6month","weight":-0.5443},{"period":"1year","weight":-0.715},{"period":"ytd","weight":-0.3721}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":-0.033},{"period":"3month","weight":-0.0344},{"period":"6month","weight":-0.0148},{"period":"1year","weight":0.088},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.08143},{"month":2,"riseRate":0.5,"avgChangeRate":0.038835},{"month":3,"riseRate":0,"avgChangeRate":-0.190829},{"month":4,"riseRate":0,"avgChangeRate":-0.071292},{"month":5,"riseRate":0.333333,"avgChangeRate":0.035781},{"month":6,"riseRate":0.333333,"avgChangeRate":0.042157},{"month":7,"riseRate":1,"avgChangeRate":0.353182},{"month":8,"riseRate":0.5,"avgChangeRate":-0.038151},{"month":9,"riseRate":0.25,"avgChangeRate":0.046615},{"month":10,"riseRate":0.25,"avgChangeRate":-0.188172},{"month":11,"riseRate":0.25,"avgChangeRate":-0.136324},{"month":12,"riseRate":0.25,"avgChangeRate":0.041027}],"exchange":"NASDAQ","name":"Acumen Pharmaceuticals, Inc.","nameEN":"Acumen Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Acumen Pharmaceuticals, Inc.(ABOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Acumen Pharmaceuticals, Inc.(ABOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Acumen Pharmaceuticals, Inc.,ABOS,Acumen Pharmaceuticals, Inc.股票,Acumen Pharmaceuticals, Inc.股票老虎,Acumen Pharmaceuticals, Inc.股票老虎国际,Acumen Pharmaceuticals, Inc.行情,Acumen Pharmaceuticals, Inc.股票行情,Acumen Pharmaceuticals, Inc.股价,Acumen Pharmaceuticals, Inc.股市,Acumen Pharmaceuticals, Inc.股票价格,Acumen Pharmaceuticals, Inc.股票交易,Acumen Pharmaceuticals, Inc.股票购买,Acumen Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Acumen Pharmaceuticals, Inc.(ABOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Acumen Pharmaceuticals, Inc.(ABOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}